XTL Biopharmaceuticals (XTLB) News
NASDAQ: XTLBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XTLB news summary
We found 2 recent headlines mentioning XTL Biopharmaceuticals (XTLB): 2 in the past week and 2 in the past 30 days, most often from Nasdaq. XTLB is making an outsized move today, down 5.84% at $1.37, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "XTL Biopharmaceuticals Ltd. to Hold Extraordinary General Meeting to Approve Name Change to Psyga Ltd., CEO Appointment, and US$1,000,000 Private Placement", was published by Nasdaq on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest XTL Biopharmaceuticals headlines
- XTL Biopharmaceuticals Ltd. to Hold Extraordinary General Meeting to Approve Name Change to Psyga Ltd., CEO Appointment, and US$1,000,000 Private PlacementXTL Biopharmaceuticals Ltd. announced that it will hold an Extraordinary General Meeting of Shareholders on Monday, December 28, 2026. Among the key proposals, the company is seeking shareholder…Nasdaq
- XTL Biopharmaceuticals Ltd. Reports Acquisition of Psyga Bio Ltd. and Financial Results for the Six Months Ended June 30, 2026XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) (“XTL” or the “Company”) today announced financial results for the six months ended June 30, 2026. On June 30, 2026,…Nasdaq